January 1, 2002Platelets
Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease
Why the study?
Does AR-C69931MX improve inhibition of platelet aggregation compared to clopidogrel in patients with ischaemic heart disease?
Population
21 patients with ischaemic heart disease, comprising 13 patients with acute coronary syndromes and 8…
Comparison
Intravenous AR-C69931MX and in vitro addition of… vs Clopidogrel (Group 2)
Authors
Discussion
Loading...
Member takes
Implication
AR-C69931MX may enhance platelet inhibition; leaves open whether benefits extend to clinical outcomes in ischaemic heart disease.
Structured PICO
Does AR-C69931MX improve inhibition of platelet aggregation compared to clopidogrel in patients with ischaemic heart disease?
P
Population
21 patients with ischaemic heart disease, comprising 13 patients with acute coronary syndromes (Group 1) and 8 patients undergoing intracoronary stent implantation (Group 2)
I
Intervention
Intravenous AR-C69931MX (Group 1) and in vitro addition of AR-C69931MX (Group 2)
C
Comparator
Clopidogrel (Group 2)
O
Outcome
Antiplatelet effects measured by whole blood single-platelet counting aggregation assaysurrogate
AR-C69931MX provides substantially greater P2Y12 receptor blockade and inhibition of platelet aggregation compared to standard clopidogrel therapy.
Cite This Study
Storey et al. (2002) studied this question.